Trials / Withdrawn
WithdrawnNCT03241446
Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis (RA)
A Phase I, Open-Label Study to Investigate the Pharmacokinetics and Dosimetry of Tc 99m Tilmanocept Following a Single Intravenous Dose Administration in Male and Female Subjects Diagnosed With Rheumatoid Arthritis
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Navidea Biopharmaceuticals · Industry
- Sex
- All
- Age
- 30 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
A prospective, open-label, single center, study to evaluate pharmacokinetics and dosimetry of intravenously injected Tc 99m tilmanocept at three mass doses (50 µg, 200 µg, and 400 µg) radiolabeled with 10 millicuries (mCi) Tc 99m.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tilmanocept | Intravenously administered Technetium Tc 99m tilmanocept |
Timeline
- Start date
- 2017-09-01
- Primary completion
- 2018-01-01
- Completion
- 2018-03-01
- First posted
- 2017-08-07
- Last updated
- 2018-10-09
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03241446. Inclusion in this directory is not an endorsement.